COPENHAGEN, Denmark and CAMBRIDGE, Mass., Feb. 9, 2024 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic treatment for the bleeding disorder Glanzmann Thrombasthenia (Glanzmann). The data were presented as one of 10 abstracts selected for the SLAM oral presentation session at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) held this week in Frankfurt, Germany.
COPENHAGEN, Denmark and CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced today that it has completed Phase 1, the single ascending dose part, and transitioned to Phase 2, the multiple ascending dose part, of its Phase 1/2 clinical study of HMB-001 in Glanzmann Thrombasthenia (GT), a platelet disorder that causes severe, potentially life-threatening bleeding episodes.
COPENHAGEN, Denmark and BOSTON, June 24, 2023 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced results today from preclinical research of HMB-001 in models of factor VII (FVII) deficiency at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress in Montreal.
COPENHAGEN, Denmark and BOSTON, June 15, 2023 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced today it will present data from preclinical research of HMB-001 in Factor VII (FVII) deficiency at the upcog International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress, June 24 – 28, in Montreal.
While hemophilia has soaked up clinical attention and investor dollars for decades, it’s come at the expense of a range of intriguingly named but less well-known blood clotting disorders. That’s where Hemab Therapeutics comes in.
Hemab Therapeutics, led by Alnylam vet Benny Sorensen and chaired by John Maraganore, has raised $135 million from a new crop of investors as it begins pushing its blood disorder programs into the clinic.
Hemab Therapeutics has announced the dosing of the first patient in a Phase I/II clinical trial of its bispecific antibody HMB-001 to treat severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).
Hemab Therapeutics, a biotechnology company, unveiled its lead candidate, HMB-001, a novel bispecific antibody with potential for the treatment of Glanzmann Thrombasthenia (GT) and other rare bleeding disorders. The company presented promising preclinical data on HMB-001 during the 2022 European Association for Haemophilia and Allied Disorders Virtual Congress (EAHAD 2022), held February 2-4, 2022.
COPENHAGEN, Denmark and BOSTON, Feb. 4, 2022 /PRNewswire/ -- Hemab Therapeutics, a biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombosis disorders, today unveiled its lead candidate, HMB-001, a novel bispecific antibody with potential for the treatment of Glanzmann Thrombasthenia (GT) and other rare bleeding disorders. The company presented promising preclinical data on HMB-001 during the 2022 European Association for Haemophilia and Allied Disorders Virtual Congress, held February 2-4, 2022.